Polymorphism of tandem repeat in promoter of 5-lipoxygenase in ASA-intolerant asthma: a positive association with airway hyperresponsiveness
Article first published online: 6 MAY 2005
DOI: 10.1111/j.1398-9995.2005.00780.x
Additional Information
How to Cite
Kim, S.-H., Bae, J.-S., Suh, C.-H., Nahm, D.-H., Holloway, J. W. and Park, H.-S. (2005), Polymorphism of tandem repeat in promoter of 5-lipoxygenase in ASA-intolerant asthma: a positive association with airway hyperresponsiveness. Allergy, 60: 760–765. doi: 10.1111/j.1398-9995.2005.00780.x
Publication History
- Issue published online: 6 MAY 2005
- Article first published online: 6 MAY 2005
- Accepted for publication 1 October 2004
- Abstract
- Article
- References
- Cited By
Keywords:
- 5-lipooxygenase;
- 5-lipoxygenase-activating protein;
- aspirin-intolerant asthma;
- bronchial hyperresponsiveness;
- tandem repeat polymorphism
Background: 5-Lipooxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) are known as key enzymes in cysteinyl-leukotriene (cys-LT) production, critical mediators in aspirin acetylsalicyclic acid (ASA)-intolerant asthma (AIA). To date, studies of the promoter region of ALOX5 gene has revealed the potential influence of a variable number of tandem repeats of a Sp1- and Egr1-binding motif, on the transcription rate.
Methods: To understand the pathological process that arises from cys-LT overproduction in AIA, we genotyped ALOX5 Sp1 and ALOX5AP poly(A) repeat promoter polymorphism by fluorescent-based capillary electrophoresis in the Korean population.
Results: No significant differences in allele and genotype frequencies of the ALOX5 and ALOX5AP promoter polymorphisms were observed between the three groups. However, there was a strong association of the ALOX5 Sp1 repeat polymorphism with airway hyperresponsiveness (AHR; PC20 methacholine); AIA patients carrying a mutant allele (n > 5 or n < 5 repeats) showed increased AHR compared to AIA patients with wild-type genotype (P = 0.003).
Conclusion: Although the alleles of the ALOX5 and ALOX5AP promoter cannot be considered as a prominent risk factor in the development of AIA, the genetic variant of tandem repeat (GGGCGG; Sp1-binding motif) in ALOX5 promoter is associated with the severity of airway hyperresponsiveness in AIA patients.

1398-9995/asset/olbannerleft.gif?v=1&s=2207070238298c1b0c4b1e73fa97140fa65e5f81)
1398-9995/asset/olbannerright.gif?v=1&s=c902da976bf6db24fc36ec0480207615a3d14921)
